Fig. 6
WTAP-mediated m6A modification enhanced circCCAR1 stability via IGF2BP3. A m6A enrichment in circCCAR1. ***p < 0.001 vs. IgG. B Diagram showing the position of m6A motifs with a high combined score within circCCAR1. C CircCCAR1 levels in HCC cells after treatment with MAO-circCCAR1 or MAO-NC. ***p < 0.001 vs. MAO-NC. D WTAP and IGFBPs levels in pulldown assays using a biotinylated antisense oligomer targeting the junction of circCCAR1. E The binding of IGF2BPs and circCCAR1 was confirmed by RIP assay. ***p < 0.001 vs. IgG. F The m6A enrichment in circCCAR1 in HCC cells after WTAP knockdown. ***p < 0.001 vs. sh-NC. G IGF2BP3 enrichment in circCCAR1 in HCC cells after WTAP knockdown. ***p < 0.001 vs. sh-NC. H CircCCAR1 levels in HCC cells after WTAP knockdown or IGF2BP3 knockdown. ***p < 0.001 vs. sh-NC. I CircCCAR1 levels in HCC cells after WTAP overexpression or IGF2BP3 knockdown. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control; ##p < 0.01, ###p < 0.001 vs. sh-IGF2BP3#2. J Stability of circCCAR1 in HCC cells after WTAP overexpression or IGF2BP3 knockdown with actinomycin D treatment. ***p < 0.001 vs. control; ###p < 0.001 vs. sh-IGF2BP3#2